Where does Arcturus Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Arcturus Therapeutics, Inc. ranks #5,736 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Arcturus Therapeutics, Inc. hold?

Arcturus Therapeutics, Inc. holds 59 US utility patents granted between 2015 and 2025, spanning 15 technology areas.

What is Arcturus Therapeutics, Inc.'s Innovation Score?

Arcturus Therapeutics, Inc. has an Innovation Score of 44.1 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Arcturus Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Arcturus Therapeutics, Inc.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Arcturus Therapeutics, Inc.'s patents?

Arcturus Therapeutics, Inc.'s patents average 18.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Arcturus Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Arcturus Therapeutics, Inc.

Q: What technology areas does Arcturus Therapeutics, Inc. focus on?

Arcturus Therapeutics, Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 47 patents, ranking #210 of 4,144 assignees active in that subclass. Grants appear in 15 CPC subclasses total.

USPTO PatentsView assignee record - 59 granted patents across 15 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Arcturus ranks #5,736 of 49,997 tracked US assignees by granted-patent volume, with 59 patents across 15 technology areas.

#5,736
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.1/100): 18.7
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5736 · US Corporation #5,736 · 59 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 59 grants
UPPER-Q #5,736/49,997
PHOTO-FINISH Accuvein
CPC-FOCUS C12N · 15 areas
INNOV-PAR 44.1/100
CLAIMS-RICH 18.7 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Accuvein, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Arcturus’s 44.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.1 pts (32%) Velocity 5.0 pts (11%) Breadth 13.7 pts (31%) Claim depth 11.2 pts (25%)

Qualcomm Incorporated · highest

85
Arcturus Therapeutics · this assignee

44
Celera · near

44
Linet Spol S R O · near

44
Mobiletron · near

44
PolyOne · near

44
3D Lighting… · lowest

7

What this shows Arcturus's Innovation Score is 44.1/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Arcturus?

Each dot is one of Arcturus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Arcturus’s own 18.7 claims/patent is ABOVE the 13.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Arcturus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Arcturus's grants concentrate

Arcturus Therapeutics, Inc. is a focused PatentsView assignee: 15 CPC subclasses with 79.7% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2019 (9 grants) versus a trough of 1 in 2015. By volume, Arcturus sits between Zonar Systems, Inc. and Aerin Medical Inc..

Arcturus's three-year grant acceleration

From 2019–2021 to 2022–2024, Arcturus Therapeutics, Inc. moved from 20 to 15 grants (0.75x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Zonar Systems

60
[24]7 ai

60
mophie

60
Alaxala Networks

59
Arris Technology

59
Auras Technology

59
Accuvein

59
Aerin Medical

59
Arcturus Therapeu… ◀

59

What this shows Arcturus holds 59 patents at rank #5,734, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Arcturus

By rank, the assignees closest to #5,734 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Arcturus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Arcturus, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Arcturus ranks #210 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

PolyOne Corporation 44 Celera, Inc. 44 Mobiletron Electronics Co., Ltd. 44 Linet Spol. S R.O 44

Similar claim depth

Nearest assignees by average claims per patent (18.7 here).

Malta Inc. 18.7 avg Braskem S.A. 18.7 avg Dorel Juvenile Group, Inc. 18.7 avg Samsara Inc. 18.7 avg

Arcturus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Arcturus Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.7%
2016	4	6.8%
2017	6	10.2%
2018	6	10.2%
2019	9	15.3%
2020	7	11.9%
2021	4	6.8%
2022	3	5.1%
2023	5	8.5%
2024	7	11.9%
2025partial year	7	11.9%

Which technologies does Arcturus Therapeutics, Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 47

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 46

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 33

C07C - Acyclic OR Carbocyclic Compounds 18

C07J - Steroids 12

C11C - Fatty Acids From Fats, Oils OR WAXES; CANDLES; Fats, Oils OR Fatty Acids BY Chemical Modification OF Fats, Oils, OR Fatty Acids Obtained Therefrom 10

C07K - Peptides 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

C12Y - Enzymes 5

Y02A - Technologies FOR Adaptation TO Climate Change 4

A23D - Edible Oils OR Fats, e.g. Margarines, Shortenings OR Cooking Oils 2

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

C07D - Heterocyclic Compounds 1

Top 15 of 15 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Arcturus Therapeutics, Inc.'s patent record in context - here's where to go next.

Arcturus Therapeutics, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 79.7% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #5,736 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Arcturus Therapeutics, Inc. against Zonar Systems, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.